Nrf2, A Target for Precision Oncology in Cancer Prognosis and Treatment

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Nuclear factor-erythroid 2-related factor (Nrf2) is a key regulator of cellular redox homeostasis.
• While Nrf2 typically suppresses cancer initiation in normal cells, it can promote proliferation in transformed cells.
• Mutations in Nrf2 lead to protein stabilization and accumulation in tumor cells, contributing to cancer progression.

Purpose of the Study:

• To explore the dual role of Nrf2 in cancer, focusing on the impact of its mutations.
• To highlight the significance of understanding Nrf2 genetic alterations for cancer prognosis and treatment.
• To discuss potential therapeutic strategies targeting Nrf2 mutations in cancer therapy.

Main Methods:

• Review of existing literature on Nrf2 function, mutations, and cancer biology.
• Analysis of the implications of Nrf2 hyperactivation in tumor cells.
• Exploration of therapeutic interventions including small molecules, RNAi, and genome editing.

Main Results:

• Mutant Nrf2 enhances cancer cell proliferation, invasiveness, and resistance to chemotherapy and radiotherapy.
• Nrf2 mutations are associated with poor clinical outcomes in cancer patients.
• Targeting Nrf2 mutations offers a promising avenue for precision cancer medicine.

Conclusions:

• Understanding Nrf2 mutations is critical for advancing precision medicine in oncology.
• Therapeutic strategies like CRISPR-Cas9 targeting Nrf2 present new possibilities for cancer treatment.
• Further research into Nrf2's role in cancer is essential for improving patient prognosis and treatment efficacy.